{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T16:07:59Z","timestamp":1780416479888,"version":"3.54.1"},"reference-count":43,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Patient Related Outcome Measures"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/1179271x.2026.2672471","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T15:22:43Z","timestamp":1780413763000},"page":"35-48","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Content validity of the Familial Chylomicronemia Syndrome Symptoms and Impacts Scale (FCS-SIS) for severe hypertriglyceridemia (sHTG)"],"prefix":"10.1080","volume":"17","author":[{"given":"Asia","family":"Sikora Kessler","sequence":"first","affiliation":[{"name":"Health Economics & Outcomes Research, Ionis Pharmaceuticals Inc.","place":["Carlsbad, US"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tammy Michelle","family":"Brown","sequence":"additional","affiliation":[{"name":"Patient-Centered Outcomes Assessment, RTI Health Solutions","place":["Durham, US"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonita","family":"Basnyat","sequence":"additional","affiliation":[{"name":"Patient-Centered Outcomes Assessment, RTI Health Solutions","place":["Durham, US"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Yarlas","sequence":"additional","affiliation":[{"name":"Health Economics & Outcomes Research, Ionis Pharmaceuticals Inc.","place":["Carlsbad, US"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Dine","sequence":"additional","affiliation":[{"name":"Patient-Centered Outcomes Assessment, RTI Health Solutions","place":["Durham, US"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2024.09.008"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1210\/js.2019-00214"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2025.08.012"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcm.2019.03.001"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-024-01574-9"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2010.11.008"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvz035"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-3213"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2023.05.048"},{"key":"#cr-split#-e_1_3_3_11_1.1","unstructured":"National Center for Advancing Translational Sciences. Familial chylomicronemia syndrome: National Institutes of Health (NIH). 2024 [updated 2024 Jul 9"},{"key":"#cr-split#-e_1_3_3_11_1.2","unstructured":"cited 2025 Oct 31]. Available from: https:\/\/rarediseases.info.nih.gov\/diseases\/6414\/familial-chylomicronemia-syndrome."},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-025-02658-8"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/metabo13050621"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-0552"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11789-012-0042-x"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.2019.0825"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2020.04.009"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-022-01525-5"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0000000000000704"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2025.03.013"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2025.04.195"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2025.04.190"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-023-02927-8"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/17446651.2024.2365787"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.593931"},{"key":"e_1_3_3_26_1","unstructured":"Ionis Pharmaceuticals Inc. TRYNGOLZA\u2122 (olezarsen) product fact sheet. Ionis Pharmaceuticals Inc.; 2024 [updated Dec 2024; cited 2025 Jul 17]. Available from: https:\/\/ionis.com\/sites\/default\/files\/2024-12\/TRYNGOLZA-Product-Fact%20Sheet-FINAL.pdf."},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1177\/10600280251332500"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2400201"},{"key":"e_1_3_3_29_1","unstructured":"EMA. Tryngolza. European Medicines Agency; 2025 [updated 2025 Oct 17; cited 2025 Oct 20]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/tryngolza."},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1186\/s41687-021-00347-5"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.2147\/PROM.S441583"},{"key":"e_1_3_3_32_1","unstructured":"ClinicalTrials.gov NCT05079919. A study of olezarsen (ISIS 678354) administered to participants with severe hypertriglyceridemia. 2025 [updated 29 January 2025;17 July 2025]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05079919."},{"key":"e_1_3_3_33_1","unstructured":"ClinicalTrials.gov NCT05552326. A study of olezarsen administered subcutaneously to participants with severe hypertriglyceridem. 2025 [updated 29 January 2025;17 July 2025]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05552326."},{"key":"e_1_3_3_34_1","unstructured":"Ionis Pharmaceuticals Inc. Severe hypertriglyceridemia (sHTG) fact sheet. Carlsbad CA: Ionis Pharmaceuticals Inc. 2024 [cited 2025 Oct 31]. Available from: https:\/\/ionis.com\/media-kit\/sHTG-factsheet."},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1177\/1049732305276687"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1020909529486"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11135-017-0574-8"},{"key":"e_1_3_3_38_1","unstructured":"ICH. ICH harmonised guideline integrated addendum to ICH E6(R1): Guideline for Good Clinical Practice ICH E6(R2): International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use. 2025 [cited 2025 Sep 15]. Available from: https:\/\/ichgcp.net\/."},{"key":"e_1_3_3_39_1","unstructured":"FDA. Patient-focused drug development: selecting developing or modifying fit-for-purpose clinical outcome assessments. Guidance for industry food and drug administration staff and other stakeholders. Food and Drug Administration; 2025 [updated Oct; cited 2025 Oct 22]. Available from: https:\/\/www.fda.gov\/media\/159500\/download."},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s41669-019-0155-y"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2023.108544"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2018.06.814"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.acvdsp.2018.10.261"}],"container-title":["Patient Related Outcome Measures"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/1179271X.2026.2672471","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T15:22:52Z","timestamp":1780413772000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/1179271X.2026.2672471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/1179271X.2026.2672471"],"URL":"https:\/\/doi.org\/10.1080\/1179271x.2026.2672471","relation":{},"ISSN":["1179-271X"],"issn-type":[{"value":"1179-271X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,27]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=dpro20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=dpro20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-12-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-27","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}